BiotechTube

Tirabrutinib + Rituximab + Temozolomide

Phase 3Recruiting
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed/Refractory Primary Central Nervous System Lymphoma

Conditions

Relapsed/Refractory Primary Central Nervous System Lymphoma

Trial Timeline

Mar 1, 2026 โ†’ Dec 1, 2029

NCT ID
NCT07104032

About Tirabrutinib + Rituximab + Temozolomide

Tirabrutinib + Rituximab + Temozolomide is a phase 3 stage product being developed by Ono Pharmaceutical for Relapsed/Refractory Primary Central Nervous System Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07104032. Target conditions include Relapsed/Refractory Primary Central Nervous System Lymphoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07104032Phase 3Recruiting

Competing Products

20 competing products in Relapsed/Refractory Primary Central Nervous System Lymphoma

See all competitors
ProductCompanyStageHype Score
agenT-797MiNK TherapeuticsPhase 1
25
Valemetostat TosylateDaiichi SankyoPhase 2
52
Eribulin mesylateEisaiPhase 2
52
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + EpcoritamabEli LillyPhase 1/2
41
ISB 1342Glenmark PharmaceuticalsPhase 1
33
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
77
Linperlisib ๏ผ› RituximabJiangsu Hengrui MedicinePhase 1/2
41
Epcoritamab + Epcoritamab, lenalidomide and rituximabAbbViePhase 2
52
EtentamigAbbViePhase 1
33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
77
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + DaratumumabAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
33
ABT-199 + bortezomib + dexamethasoneAbbViePhase 1
33
Venetoclax + DexamethasoneAbbViePhase 1/2
41
ABBV-453 + Dexamethasone + Daratumumab + LenalidomideAbbViePhase 1
33
mRNA-2752 + DurvalumabAstraZenecaPhase 1
33
AZD4573AstraZenecaPhase 2
52
Moxetumomab PasudotoxAstraZenecaPre-clinical
23
Administration of AZD6738AstraZenecaPhase 1
33
BlinatumomabAmgenPhase 2
51

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77